Meeting: 2017 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5506 Citation: J Clin Oncol 35, 2017 (suppl; abstr 5506) Authors: Jonathan A. Ledermann, Andrew C. Embleton, Timothy Perren, et. al. Background: ICON6 is a three-arm double-blind, placebo-controlled phase 3 trial of cediranib in platinum-sensitive relapsed ovarian cancer (NCT00532194). The...
Pro zobrazení tohoto obsahu je třeba být přihlášen.